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Abstract 
The objective of present work was to formulate and evaluate sustained 
release matrix tablets of levofloxacin for treating microbial infections 
effectively. Levofloxacin is the active component of the racemate 
ofloxacin, and used for treating a variety of clinical conditions such as 
lower respiratory tract infections, acute sinusitis, uncomplicated skin and 
soft-tissue infections and complicated urinary tract infections. Different 
formulations were prepared by wet granulation method using various 
release rate controlling hydrophilic polymers. The formulations were 
evaluated for hardness, weight variation, friability and drug content 
uniformity. The in vitro release of drug from the formulations was 
studied in pH 1.2 acidic buffer and pH 6.8 phosphate buffer, and it was 
found that the prepared tablets were able to sustain the release of the 
drug. The release of levofloxacin from the tablets was diffusion 
controlled and the release mechanism was   non-Fickian. For conclusion, 
the developed formulations may reduce the dosing intervals, reduce the 
dose related side effects and increase the drug’s efficacy for treating 
infections. 
Keywords: Matrix tablets, levofloxacin, HPMC, guar gum, xantham 
gum, locust bean gum, Amorphophallus starch. 
 
Introduction 
Though, Dr. Paul Ehrlich’s concept of ‘magic 
bullet’ realized late, helps to solve the problems 
of unwanted side effects of drugs and optimizing 
the therapy in its true sense. The sustained and 
controlled release drug delivery can be 
considered as the progenitor of magic bullet 
concept [1]. The main objective of developing a 
sustained release dosage form is to maintain drug 
concentration in the blood for a prolonged period 
of time, which results reduction in dosing interval 
and reduce the dose related side effects. Drugs 
with low therapeutic index and short half life are 
ideal candidates for sustained drug delivery [2]. 
Oral route is the most convenient route for the 
administration of drugs. This is because of more  
 
flexibility in dosage form design for oral route 
than for parenteral or any other route. Oral 
sustained release dosage forms such as matrix 
tablets have been getting much attention by the 
researches due to several advantages [3]. Many 
drugs are available in the market as sustained 
release tablets due to the fact that they are usually 
easy and economical to formulate, greater 
acceptance by the people and greater patient 
compliance.  
Sustained release matrix tablets can be 
formulated using hydrophilic polymers such as 
hydroxy propyl methyl cellulose (HPMC), guar 
gum, xantham gum, locust bean gum, sodium 
carboxy methyl cellulose, sodium alginate, etc. 
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[4]. The release of drug from the matrix tablets 
formulated with hydrophilic polymers can be 
controlled by polymer swelling and cross-linking 
[5]. Many studies have been carried out to find 
out the effectiveness of hydrophilic polymers to 
fabricate sustained release matrix tablets to 
deliver hydrophilic and hydrophobic drugs [4,6]. 
Hydroxy propyl methyl cellulose, semisynthetic 
nonionic cellulose ether, is widely used in 
controlled-release dosage forms due to its 
versatility, nontoxic nature, and its pH 
independence.  
 
Fluoroquinolones are synthetic antibacterial 
agents. They have received much attention 
recently by researches owe to their ability to treat 
a wide range of infections. Nalidixic acid, the 
first fluoroquinolone, was introduced in 1962 [7]. 
Subsequently, numerous nalidixic acid 
derivatives have been introduced to treat a wide 
range of bacterial infections [8]. Levofloxacin is 
one among them and has wider clinical usage. It 
is the pure (-)-(S)-enantiomer of the racemate 
ofloxacin [9]. Levofloxacin inhibits bacterial cell 
division by inhibiting DNA gyrase, bacterial type 
II topoisomerase, and topoisomerase IV. It is 
rapidly and completely absorbed after oral 
administration. It has a half life is 6 to 8 h. It has 
been used for treating various conditions such as 
pneumonia, chronic bronchitis and sinus, urinary 
tract, kidney, prostate and skin infections [10]. 
The development of oral sustained release matrix 
tablets of levofloxacin is highly useful 
considering the above said facts. This is expected 
to maintain drug concentration in the blood for a 
prolonged period of time which inturn reduce the 
dosing intervals and increase patient compliance.  
Hence the present work was undertaken with an 
objective of to formulate and evaluate sustained 
release matrix tablets of levofloxacin for treating 
microbial infections in an effective manner. 
 
Materials and methods 
Materials 
Levofloxacin was a kind gift from Cadila 
Pharmaceuticals, Ahmadabad, India. Hydroxy 
propyl methyl cellulose was purchased from Otto 
chemicals, India. Amorphophallus starch was 
obtained as a gift from Central Tuber Crops 
Research Institute, Thiruvananthapuram, India. 
Microcrystalline cellulose (Avicel PH 102) was a 
kind gift from Strides Arco Lab., Bangalore, 
India. All other chemicals used for the study were 
analytical grade.  
 
Methods 
Preparation of levofloxacin tablets 
Levofloxacin tablets were prepared by wet 
granulation method. Specified quantity of drug, 
polymer (HPMC or guar gum or xantham gum or 
locust bean gum or Amorphophallus starch) and 
Avicel PH 102 were weighed (Table 1) and 
mixed thoroughly. The powder mixture was 
converted into a sluggy mass using 5% starch 
paste. Granules were obtained by passing the 
sluggy mass through sieve no 12. The prepared 
granules were subjected to drying at 40oC for     4 
h. After drying, the granules were screened 
through sieve no 22 & 44 and stored for further 
studies. Specified quantity of magnesium stearate 
and talc was finally added into the granules and 
mixed thoroughly. The mixture was directly 
punched into tablets weighing about 300 mg 
containing 100 mg of levofloxacin, using rotary 
tablet compression machine (12 stations, 
Karnavati, India), using 9 mm diameter concave 
punches. The different batches of levofloxacin 
tablets were collected and stored in air tight 
containers. 
 
Evaluation of granules 
Determination of granules size by optical 
microscopy 
Mean granules size was determined using optical 
microscopy. For this, the granules were evenly 
spread on a glass slide. Granules size was 
determined by measuring the individual granules 
along the longest axis and the shortest axis (cross 
shaped measurement) using an optical 
microscope after calibration. Average of these 
two readings is the mean diameter of granules. In 
each batch, the diameter of minimum 50 granules 
was determined. 
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Table 1. Formula for the preparation of levofloxacin sustained release matrix tablets. 
Ingredients Batch 
code Drug 
(mg) 
HPMC 
(mg) 
AS 
(mg) 
GG 
(mg) 
XG 
(mg) 
LBG 
(mg) 
MCC 
(mg) 
SP 
(5%) 
MS 
(mg) 
Talc  
(mg) 
F-1 100 - - - - - 191 q.s 6 3 
F-2 100 30 - - - - 161 q.s 6 3 
F-3 100 60 - - - - 131 q.s 6 3 
F-4 100 90 - - - - 101 q.s 6 3 
F-5 100 120 - - - - 71 q.s 6 3 
F-6 100 150 - - - - 41 q.s 6 3 
F-7 100 - 30 - - - 161 q.s 6 3 
F-8 100 - 60 - - - 131 q.s 6 3 
F-9 100 - 90 - - - 101 q.s 6 3 
F-10 100 - 120 - - - 71 q.s 6 3 
F-11 100 - 150 - - - 41 q.s 6 3 
F-12 100 - - 30 - - 161 q.s 6 3 
F-13 100 - - 60 - - 131 q.s 6 3 
F-14 100 - - 90 - - 101 q.s 6 3 
F-15 100 - - 120 - - 71 q.s 6 3 
F-16 100 - - 150 - - 41 q.s 6 3 
F-17 100 - - - 30 - 161 q.s 6 3 
F-18 100 - - - 60 - 131 q.s 6 3 
F-19 100 - - - 90 - 101 q.s 6 3 
F-20 100 - - - 120 - 71 q.s 6 3 
F-21 100 - - - 150 - 41 q.s 6 3 
F-22 100 - - - - 30 161 q.s 6 3 
F-23 100 - - - - 60 131 q.s 6 3 
F-24 100 - - - - 90 101 q.s 6 3 
F-25 100 - - - - 120 71 q.s 6 3 
F-26 100 - - - - 150 41 q.s 6 3 
HPMC- hydroxypropyl methylcellulose; AS- Amorphophallus starch; GG- guar gum;              
XG- xanthum gum; LBG- locust bean gum; MCC- microcrystalline cellulose; SP- starch paste; MS- magnesium stearate; q.s- 
quantity sufficient. 
 
Determination of bulk density 
Bulk density was determined by using bulk 
density apparatus. It is the ratio of total mass of 
powder to the bulk volume of powder. It was 
measured by pouring the weighed granules into 
the graduated measuring cylinder of the bulk 
density apparatus and the volume was noted.  
 
Determination of tapped density 
Tapped density is the ratio of total mass of 
powder to the tapped volume of powder. This 
was measured by tapping the powder to constant 
volume.  
 
Determination of Carr’s index and Hausner’s 
ratio 
The flow properties of granules are indicated by 
Carr’s index. It is given in percentage and 
determined by the formula (Dt-Db/Dt) × 100; 
where Dt is the tapped density and Db is the bulk 
density. The Hausner’s ratio is determined by the 
following formula (Dt/Db). 
 
Determination of angle of repose 
Angle of repose is defined as the maximum angle 
possible between the surface of a pile of powder 
and the horizontal plane. This was determined by 
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passing required quantities of levofloxacin 
granules through a funnel from a particular height 
(2 cm) onto a flat surface until it formed a heap, 
which touched the tip of the funnel. The height 
and radius of the heap were measured. The angle 
of repose was determined by using the formula; 
Angle of repose,θ = tan-1 (h/r); where, h-height of 
the pile in cm and r-radius of the pile. 
 
Evaluation of sustained release matrix tablets of 
levofloxacin 
Hardness 
The hardness of different batches of prepared 
tablets was tested by using Monsanto hardness 
tester and given in kg/cm2. 
 
Weight variation test 
For this, 20 tablets were taken randomly from 
each batch and weighed separately, and the 
average weight was determined. The weight 
variation was determined by calculating the 
percent deviation of each tablet’s weight against 
the average weight according to the official 
method [11]. 
 
Friability 
Twenty tablets were taken from each batch 
randomly and the friability was determined using 
Roche Friabilator and expressed in percentage. 
 
Drug content uniformity 
The prepared levofloxacin tablets were tested for 
their drug content. Six tablets of each batch were 
finely powdered; 100 mg of powder was 
accurately weighed and the drug was completely 
extracted with pH 1.2 acidic buffer. The solution 
was filtered and the levofloxacin content was 
determined by UV spectrophotometer (Shimadzu 
(UV-1700), Japan) at 293 nm. 
 
In vitro drug release studies 
The release of drug from different batches of 
prepared tablets was studied by using USP 
dissolution apparatus type II [12]. The dissolution 
medium used was 900 ml of acidic buffer of pH 
1.2 for 2 h and phosphate buffer of pH 6.8 for 10 
h. The temperature was maintained at 37°C ± 
0.5°C and the stirring rate was 100 rpm. Samples 
were withdrawn at regular time intervals and the 
same volume was replaced with fresh dissolution 
medium. The samples were measured by UV 
Spectrophotometer at 293 nm against a blank.  
 
 
Release kinetics 
The in vitro release data of drug levofloxacin 
from selected formulations (F5, F16, F20 and 
F26) were fitted to various kinetic equations such 
as zero order, first order, Higuchi and 
Korsmeyer-Peppas release kinetics model [13]. 
For zero order (Q = Q0 – K0t) the graph was 
plotted in cumulative percent of drug released Vs 
time, first order release (In Q = In Q0 – K1 t) the 
graph was plotted in log cumulative percent of 
drug remaining vs time. In the case of Higuchi (Q 
= K2 t1/2) the graph was plotted in cumulative 
percent of drug released vs squre root of time, 
and for Korsmeyer-Peppas (Q/Q0 = K tn) the 
graph was plotted in log cumulative percent of 
drug released vs log time.  Where, K0 to K2 were 
release rate constants, Q/Q0  was fraction of drug 
released at time t, K was a constant and n was 
diffusion constant that indicates general operating 
release mechanism.  
 
Results & discussion 
Characterization of levofloxacin sustained 
release matrix tablets 
Pre-compression parameters 
Granulation is an important step in the 
preparation of tablets as the physical properties of 
granules play a vital role in the release of drug 
from the sustained release tablets. The 
levofloxacin granules were prepared by wet 
granulation method. The prepared granules of 
different batches were evaluated for their 
granules size, angle of repose, bulk density, 
tapped density, compressibility index and 
Hausner’s ratio, and the results are shown in 
Table 2. The granules have an average size in the 
range of 0.448 ± 0.11 to 0.683 ± 0.15 mm, which 
indicates narrow size distribution. The bulk 
densities of the granules were found to be in the 
range of 0.400 to 0.48 gm/ml. The angle of 
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repose varied from 27.51 ± 0.18o to 31.37 ± 
0.18o. The low values of angle of repose indicate 
the free flowing nature of the granules. The 
tapped densities were ranged 0.444 to 0.545 
gm/ml and the Carr’s indexes were in the range 
of 9.05 to 13.53. Hausner’s ratio was found in the 
range of 1.02 ± 0.04 to 1.15 ± 0.09 and the values 
showed the low interparticle friction between the 
granules. The values of compressibility index 
further confirmed the good compressibility of the 
prepared granules [14,15].  
 
Post-compression parameters 
The tablets of levofloxacin were prepared by wet 
granulation method. The prepared tablets were 
evaluated for their weight variation, hardness, 
friability and drug content uniformity, and the 
results are presented in Table 3. The weight 
variation was within the prescribed limits and it 
was varied between 0.09 ± 0.024 to 1.4 ± 0.02 %. 
Hardness was in the range of 4.5 ± 0.14 to 7.7 ± 
0.35 kg/cm2. Friability was less than 1% in all the 
batches, which indicates tablet’s ability to 
withstand shock during the time of transportation 
and handling. Drug content was uniform within 
the prepared batches and ranged between 72.87 ± 
0.34 to 96.84 ± 0.16%. It is clear from the above 
said factors that the physical parameters 
evaluated for the different batches of tablets were 
within the prescribed limits [11]. 
Table 2. Physical evaluation of levofloxacin granules  
Parameter Batch  
Code Mean size 
(mm)** 
Bulk density  
(gm/ml)* 
Tapped density 
(gm/ml)* 
Carr’s 
Index (%) 
Hausner’s 
ratio 
Angle of 
repose (°)* 
F-1 0.66 ± 0.25 0.40 ± 0.06 0.444 ± 0.05 10.01 ± 0.14 1.11 ± 0.06 29.05 ± 0.25
F-2 0.683 ± 0.15 0.480 ± 0.03 0.545 ± 0.03 11.92 ± 0.12 1.13 ± 0.02 29.74 ± 0.24
F-3 0.575 ± 0.12 0.440 ± 0.04 0.500 ± 0.02 12.00 ± 0.15 1.13 ± 0.05 27.75 ± 0.15
F-4 0.570 ± 0.16 0.432 ± 0.05 0.490 ± 0.04 11.83 ± 0.13 1.13 ± 0.03 29.74 ± 0.17
F-5 0.520 ± 0.05 0.416 ± 0.03 0.476 ± 0.05 12.60 ± 0.09 1.14 ± 0.04 29.05 ±0.26 
F-6 0.530 ± 0.21 0.409 ± 0.04 0.473 ± 0.03 13.53 ± 0.24 1.15 ± 0.09 29.30 ± 0.14
F-7 0.539 ± 0.06 0.412 ± 0.04 0.460 ± 0.05 10.43 ± 0.20 1.11 ± 0.07 29.60 ± 0.34
F-8 0.612 ± 0.04 0.420 ± 0.03 0.466 ± 0.06 9.87 ± 0.14 1.10 ± 0.06 28.52 ± 0.14
F-9 0.448 ± 0.11 0.421 ± 0.05 0.476 ± 0.04 11.55 ± 0.07 1.13 ± 0.03 29.05 ± 0.26
F-10 0.536 ± 0.05 0.408 ± 0.03 0.450 ± 0.05 9.30 ± 0.17 1.10 ± 0.08 27.51 ± 0.18
F-11 0.659 ± 0.20 0.412 ± 0.05 0.454 ± 0.03 9.20 ± 0.23 1.07 ± 0.04 30.76 ± 0.21
F-12 0.538 ± 0.16 0.410 ± 0.02 0.463 ± 0.03 11.64 ± 0.18 1.12 ± 0.07 30.76 ± 0.36
F-13 0.507 ± 0.04 0.400 ± 0.02 0.444 ± 0.06 10.01 ± 0.32 1.11 ± 0.03 29.60 ± 0.12
F-14 0.488 ± 0.15 0.420 ± 0.03 0.474 ± 0.03 11.49 ± 0.12 1.12 ± 0.02 29.05 ± 0.24
F-15 0.545 ± 0.12 0.411 ± 0.05 0.456 ± 0.02 10.01 ± 0.15 1.10 ± 0.05 28.52 ± 0.15
F-16 0.537 ± 0.06 0.418 ± 0.05 0.472 ± 0.04 11.44 ± 0.13 1.12 ± 0.03 29.60 ± 0.17
F-17 0.542 ± 0.05 0.405 ± 0.03 0.450 ± 0.05 9.05 ± 0.09 1.06 ± 0.04 30.71 ± 0.26
F-18 0.535 ± 0.21 0.411 ± 0.04 0.455 ± 0.03 9.60 ± 0. 24 1.10 ± 0.09 29.05 ± 0.14
F-19 0.539 ± 0.06 0.430 ± 0.04 0.485 ± 0.05 11.34 ± 0.20 1.12 ± 0.07 29.60 ± 0.34
F-20 0.515 ± 0.04 0.415 ± 0.03 0.459 ± 0.06 9.50 ± 0.14 1.10 ± 0.06 28.52 ± 0.14
F-21 0.560 ± 0.11 0.411± 0.05 0.455 ± 0.04 9.60 ± 0.07 1.10 ± 0.03 28.00 ± 0.26
F-22 0.560 ± 0.15 0.405 ± 0.03 0.457 ± 0.05 11.47 ± 0.17 1.12 ± 0.08 31.37 ± 0.18
F-23 0.559 ± 0.12 0.400 ± 0.05 0.451 ± 0.03 11.32 ± 0.23 1.12 ± 0.04 30.17 ± 0.21
F-24 0.530 ± 0.06 0.414 ± 0.02 0.457 ± 0.03 9.40 ± 0.18 1.10 ± 0.07 29.60 ± 0.36
F-25 0.517 ± 0.04 0.418 ± 0.02 0.472 ± 0.06 11.44 ± 0.32 1.12 ± 0.03 29.60 ± 0.12
F-26 0.475 ± 0.05 0.424 ± 0.07 0.477 ± 0.04 11.42 ± 0.06 1.13 ± 0.05 29.05 ± 0.07
* (n=3 ± S.D)                      ** (n=50 ± S.D) 
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Table 3. Physicochemical evaluations of pantoprazole tablets 
Parameter  
Batch 
Code 
Hardness 
(kg/cm2 )* 
Friability 
(%)** 
Weight variation 
(%)** 
Drug content 
(%)*** 
F-1 5.8 ± 0.4 0.012 ± 0.03 1.1 ± 0.05 91.23 ± 0.05 
F-2 7.4 ± 0.01 0.015 ± 0.02 1.4 ± 0.02 81.5 ± 0.21 
F-3 5.7 ± 0.12 0.010 ± 0.02 0.96 ± 0.01 78.2 ± 0.15 
F-4 7.7 ± 0.35 0.018 ± 0.03 0.859 ± 0.01 72.87 ± 0.34 
F-5 6.3 ± 0.21 0.005 ±0.03 0.09 ± 0.02 96.5 ± 0.42 
F-6 5.9 ± 0.15 0.020 ± 0.02 0.65 ± 0.03 96.84 ± 0.16 
F-7 5.7 ± 0.42 0.10 ± 0.02 0.43 ± 0.02 94.93 ± 0.09 
F-8 6.5 ± 0.17 0.12 ± 0.03 0.19 ± 0.02 92.87 ± 0.48 
F-9 5.4 ± 0.16 0.6 ± 0.04 0.29 ± 0.01 83.97 ± 0.26 
F-10 6.7 ± 0.24 0.40 ± 0.02 0.14 ± 0.01 91.36 ± 0.35 
F-11 5.9 ± 0.25 0.16 ± 0.02 0.56 ± 0.02 86.9 ± 0.42 
F-12 5.8 ± 0.34 0.27 ± 0.03 0.98 ± 0.02 94.15 ± 0.13 
F-13 6.0 ± 0.18 0.33 ± 0.03 0.132 ± 0.03 92.15 ± 0.18 
F-14 5.0 ± 0.09 0.33 ± 0.03 0.234 ± 0.04 86.15 ± 0.38 
F-15 6.5 ± 0.24 0.16 ± 0.02 0.287 ± 0.02 90.76 ± 0.27 
F-16 7.0 ± 0.08 0.16 ± 0.02 0.290 ± 0.01 86.72 ± 0.36 
F-17 5.0 ± 0.13 0.1 ± 0.01 0.76 ± 0.02 94.05 ± 0.15 
F-18 6.0 ± 0.05 0.4 ± 0.01 0.56 ± 0.04 92.00 ± 0.5 
F-19 5.5 ± 0.24 0.33 ± 0.05 0.54 ± 0.63 86.10 ± 0.04 
F-20 5.7 ± 0.13 0.27 ± 0.04 0.75 ± 0.03 89.76 ± 0.08 
F-21 6.5 ± 0.12 0.33 ± 0.01 0.76 ± 0.02 85.72 ± 0.04 
F-22 4.5 ± 0.14 0.33 ± 0.07 0.86 ± 0.04 94.15 ± 0.06 
F-23 5.0 ± 0.05 0.27 ± 0.01 0.56 ± 0.03 90.15 ± 0.07 
F-24 5.5 ± 0.12 0.33 ± 0.01 0.05 ±.0.02 86.15 ± 0.02 
F-25 6.0 ± 0.04 0.15 ± 0.01 0.3 ± 0.03 91.76 ± 0.05 
F-26 5.5 ± 0.05 0.16 ± 0.02 0.12 ± 0.02 86.72 ± 0.05 
    *(n=6 ± S.D)                 **(n=20 ± S.D)             ***(n=3 ± S.D) 
 
 
 
Figure 1. In vitro drug release profile of levofloxacin from tablet formulations F1 to F6. 
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Figure 2. In vitro drug release profile of levofloxacin from tablet formulations F7 to F11. 
 
 
Figure 3. In vitro drug release profile of levofloxacin from tablet formulations F12 to F16. 
 
 
In vitro drug release studies 
Studying the release of drug from the tablets is 
important to know about the drug release pattern. 
Release of drug from a sustained release matrix 
tablets is affected by many factors which includes 
the granulation method, type of additives used, 
drug polymer ratio, pH of the dissolution medium 
and drug solubility in the dissolution medium 
[16]. The in vitro release was studied in pH 1.2 
acidic buffer for 2 h and in phosphate buffer pH 
6.8 for 10 h. The release was affected by the type 
of polymer as well as the concentration used 
(Figure 1 to Figure 5). As expected, Formulation-
1 released about 95% of its contents within an 
hour due to the fact that it was prepared without 
release controlling polymer. All the polymers 
except Amorphophallus starch extended the drug 
release over a prolonged period of time and the 
drug release from the tablets also depend on the 
nature and concentration of the polymer used. 
Among the formulations, F5, F16, F20 and F26 
have showed maximum sustained release. 
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Figure 4. In vitro drug release profile of levofloxacin from tablet formulations F12 to F16. 
 
 
                     
Figure 5. In vitro drug release profile of levofloxacin from tablet formulations F22 to F26. 
 
 
Table 4. Release kinetics of levofloxacin from tablet formulations. 
Korsmeyer-Peppas Formulation Zero order r2 First order r2 Higuchi r2 
r2 n 
F-5 0.943 0.970 0.986 0.981 0.559 
F-16 0.952 0.990 0.996 0.994 0.540 
F-20 0.934 0.991 0.993 0.987 0.635 
F-26 0.942 0.993 0.996 0.988 0.606 
Release kinetics 
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The in vitro release data obtained from 
Formulations- F5, F16, F20 and F26 was fitted to 
kinetic models such as zero order, first order, 
Higuchi and Korsmeyer-Peppas models [13] to 
explore the release mechanism and the values are 
given in Table 4. The data obtained from the 
release kinetics fitted with Higuchi model 
indicated that the release of drug from the tablets 
was depend on the square root of time. Further, it 
is important to note that a linear relationship was 
obtained for a plot of release profile verses time, 
and the regression coefficient was very close to 
zero               (r2 = 0.986, 0.996, 0.993 and 0.996 
for Formulations- F5, F16, F20 and F26 
respectively) for all the four formulations. The n 
values obtained from the Korsmeyer-Peppas 
model showed that the release mechanism was 
non-Fickian. Generally, tablets prepared with 
hydrophilic polymers show a release mechanism 
of Fickian indicating the passage of drug through 
the polymer matrix by diffusion. But, sometimes 
other factors such as rate of polymer swelling, 
polymer chain relaxation also influence the drug 
release in addition to diffusion and lead to non-
Fickian mechanism [17].  
 
Conclusion 
The sustained drug release can be obtained by 
hydrophilic polymers such as HPMC, guar gum, 
xantham gum and locust bean gum. 
Amorphophallus starch failed to prolong 
levofloxacin release from the tablets. The drug 
release also depends on the concentration and the 
nature of polymer. The drug release was diffusion 
controlled and the release mechanism was non-
Fickian. Though further in vivo studies are 
required to confirm the effectiveness of the 
prepared formulations, it can be concluded that 
the prepared formulations may reduce the dosing 
intervals, reduce the dose related side effects and 
increase the drug’s efficacy for treating various 
bacterial infections. 
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